Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31691453 | 0.88 | PIK3CA (0.36) | PIK3CATTKMAPTL3MBTL1PIK3CD | |
| SCHEMBL30748930 | 0.86 | TTK (0.42) | PIK3CATTKINSRALKMAPT | |
| SCHEMBL30749106 | 0.85 | PSEN1 (0.37) | SMN1; SMN2 | |
| SCHEMBL30749157 | 0.84 | PIK3CA (0.47) | PIK3CAINSRALKMAPTL3MBTL1 | |
| SCHEMBL30749134 | 0.75 | LRRK2 (0.43) | PIK3CATTKINSRALKLRRK2 | |
| SCHEMBL30748783 | 0.74 | AGXT (0.34) | MAPTL3MBTL1 | |
| SCHEMBL30749056 | 0.73 | TTK (0.43) | PIK3CATTKINSRALKMAPT | |
| SCHEMBL31691490 | 0.72 | PLK4 (0.40) | PIK3CAMAPTL3MBTL1PIK3CBSMN1; SMN2 | |
| SCHEMBL30748750 | 0.72 | MTOR (0.36) | — | |
| SCHEMBL30748822 | 0.71 | PSEN1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | PIK3CA 1906/4885TTK 4131/4885INSR 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.